{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T22:51:28Z","timestamp":1768690288381,"version":"3.49.0"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T00:00:00Z","timestamp":1635120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T00:00:00Z","timestamp":1635120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000156","name":"fonds de recherche du qu\u00e9bec - sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s10875-021-01162-9","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T11:12:00Z","timestamp":1635160320000},"page":"206-209","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Late-Onset Combined Immunodeficiency with Refractory CMV Disease due to ICOSL Deficiency"],"prefix":"10.1007","volume":"42","author":[{"given":"Vivian G.","family":"Loo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucie","family":"Roussel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Bernier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald C.","family":"Vinh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,25]]},"reference":[{"key":"1162_CR1","first-page":"121","volume-title":"Advances in immunology","author":"LD Notarangelo","year":"2014","unstructured":"Notarangelo LD. Chapter Four \u2014 Combined immunodeficiencies with nonfunctional T lymphocytes. In: Alt FW, editor. Advances in immunology. Academic Press; 2014. p. 121\u201390."},{"issue":"12","key":"1162_CR2","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1084\/jem.20180668","volume":"215","author":"L Roussel","year":"2018","unstructured":"Roussel L, Landekic M, Golizeh M, et al. Loss of human ICOSL results in combined immunodeficiency. J Exp Med. 2018;215(12):3151\u201364.","journal-title":"J Exp Med"},{"key":"1162_CR3","doi-asserted-by":"publisher","first-page":"5360","DOI":"10.1038\/ncomms6360","volume":"5","author":"KL Willmann","year":"2014","unstructured":"Willmann KL, Klaver S, Do\u011fu F, et al. Biallelic loss-of-function mutation in NIK causes a primary immunodeficiency with multifaceted aberrant lymphoid immunity. Nat Commun. 2014;5:5360.","journal-title":"Nat Commun"},{"issue":"7","key":"1162_CR4","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.4049\/jimmunol.1700833","volume":"199","author":"JC Lownik","year":"2017","unstructured":"Lownik JC, Luker AJ, Damle SR, et al. ADAM10-mediated ICOS ligand shedding on B cells is necessary for proper T cell ICOS regulation and T follicular helper responses. J Immunol. 2017;199(7):2305\u201315.","journal-title":"J Immunol"},{"key":"1162_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.coi.2021.03.001","volume":"72","author":"L Roussel","year":"2021","unstructured":"Roussel L, Vinh DC. ICOSL in host defense at epithelial barriers: lessons from ICOSLG deficiency. Curr Opin Immunol. 2021;72:21\u20136.","journal-title":"Curr Opin Immunol"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-021-01162-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10875-021-01162-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-021-01162-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T10:24:15Z","timestamp":1644229455000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10875-021-01162-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,25]]},"references-count":5,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1162"],"URL":"https:\/\/doi.org\/10.1007\/s10875-021-01162-9","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,25]]},"assertion":[{"value":"27 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DCV is supported by the Fonds de recherche du Qu\u00e9bec \u2013 Sant\u00e9 clinician-scientist scholar award. DCV has received research support from Cidara Therapeutics, CSL Behring, and Janssen Pharmaceutica, as well as consulting or speaker honoraria from CSL Behring, Novartis Canada, and UCB Biosciences GmbH. DCV has a patent application pending (Electronic Filing System ID: 40101099) and a report of invention submitted to McGill University (Track code: D2021-0043), neither of which are related to this manuscript. VGL has received consulting fees for Merck Canada Inc. All other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}